# Ipamorelin FAQ: Bones, IGF-1, the CJC-1295 Stack, and Safety > Ipamorelin questions answered plainly and cited — does it raise IGF-1, build muscle, help bones, make you hungry, how long it lasts, and why its development stalled. Direct, cited answers to what people actually ask — about bone, IGF-1, the CJC-1295 pairing, appetite, and where the human evidence stands. ## Does ipamorelin increase IGF-1? Not consistently in short studies. In a 15-day rat bone study, subcutaneous ipamorelin raised the longitudinal bone-growth rate dose-dependently with no change in total IGF-1 [4]. Sustained or combination protocols can raise IGF-1 downstream of the growth-hormone pulse [13], but the systemic IGF-1 response is context-dependent and was absent in several short rodent experiments [4]. ## Does ipamorelin build muscle? No controlled human muscle data exist. In animals, ipamorelin combined with a glucocorticoid raised maximum tetanic muscle tension in a steroid muscle-loss model [7], and a 2026 review reported the CJC-1295 + ipamorelin combination improved tetanic tension in mice [15]. These are animal findings; the human muscle-building claim is not established by any controlled trial [3]. ## Is ipamorelin good for bones? In rats, yes — measurably. Subcutaneous ipamorelin at 18, 90, and 450 micrograms a day raised the longitudinal bone-growth rate from 42 to 52 micrometers a day dose-dependently [4], and 12 weeks of continuous dosing increased tibial and vertebral bone mineral content [8]. It also partly rescued steroid-weakened bone [7]. All of this skeletal evidence is preclinical; no human bone outcome has been tested [3]. ## What is ipamorelin? Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively releases growth hormone by activating the ghrelin receptor (GHS-R1a) on pituitary cells [1]. Its defining trait is selectivity — it raises growth hormone without raising ACTH or cortisol, even at high doses [1]. It is a research peptide, not an approved drug [3]. ## What does ipamorelin do for you? In the body, ipamorelin triggers a discrete pulse of growth hormone via the ghrelin receptor [1]. In animals that translates to faster longitudinal bone growth [4] and added bone mineral content [8]. In humans, the evidence is thin and largely negative — its one Phase 2 trial missed its endpoint [3] — so claims of human benefit are not supported by controlled data. ## What is ipamorelin peptide? It is a five-amino-acid synthetic peptide that mimics the hunger hormone ghrelin at its receptor to release growth hormone [1]. The Aib building block at position one gives it metabolic stability [5]. It is described as the first selective growth-hormone secretagogue because it releases growth hormone cleanly, without the cortisol and prolactin rises seen with older GH-releasing peptides [1]. ## What are the risks of ipamorelin? The biggest risk is the unknown: no long-term human safety data exist, and its only Phase 2 trial (n=114) was a short seven-day IV course [3]. Mechanistic cautions apply to active cancer (IGF-1 is a mitogen) [11], diabetes (mixed glucose effects) [9], and heart disease (a class-level cardiotoxicity signal in a related agonist) [6]. Research-grade material also has unverified purity [3]. ## Does ipamorelin reduce belly fat? There is no human evidence that ipamorelin reduces belly fat. In a 2024 ferret study, intraperitoneal ipamorelin reduced cisplatin-induced body-weight loss by about 24 percent — a weight-preserving effect, not fat loss [16]. Mouse data actually show raised fat-pad weight and leptin [10]. Any "fat loss" reported by users is anecdotal and confounded by diet and training [3]. ## What are the downsides of ipamorelin? The central downside is that it does not have proven human benefit — its lone Phase 2 trial missed its endpoint [3]. Reported adverse effects (anecdotal) include a post-injection flush, increased hunger, tingling, mild water retention, and injection-site irritation. Mechanistic concerns include glucose effects [9] and a class-level cardiac signal in a related compound [6]. ## Why is ipamorelin being discontinued? Ipamorelin was never an approved product to discontinue; its clinical development stalled because its only Phase 2 trial for postoperative ileus missed its primary endpoint (25.3 vs 32.6 hours, p=0.15) and no further program followed [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list, tightening compounding-pharmacy access [3]. ## What does CJC-1295 and ipamorelin do? They raise growth hormone through two different doorways — CJC-1295 on the GHRH receptor, ipamorelin on the ghrelin receptor — which is the rationale for combining them [1]. In animals, the combination improved tetanic muscle tension in a steroid muscle-loss model [15]. No controlled human trial has tested the pairing for any outcome [3]. ## How does CJC-1295 ipamorelin work? CJC-1295 stimulates the GHRH receptor while ipamorelin stimulates the ghrelin receptor (GHS-R1a); the two pathways converge on pituitary growth-hormone release and are complementary [1]. The idea is a larger or more sustained growth-hormone signal than either alone, but this synergy is inferred from single-agent pharmacology, not demonstrated in a human combination trial [3]. ## How much CJC-1295 ipamorelin should I take? No validated human dose exists, and this site does not provide one. The combination has never been tested in a controlled human trial [3], and community subcutaneous protocols have no peer-reviewed human dosing basis — they are anecdotal, not recommended [3]. What the literature establishes is mechanism [1] and a roughly two-hour half-life [2], not a dose to take. ## Does CJC-1295 ipamorelin work? Evidence is limited to animal studies. A 2026 narrative review found CJC-1295 with ipamorelin improved maximum tetanic tension in a glucocorticoid-induced muscle-loss model in mice, while noting the evidence base is limited and not established in humans [15]. No controlled human trial supports the combination for any outcome [3]. ## How to reconstitute CJC-1295 ipamorelin 5mg? Ipamorelin is supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic water for research handling; as a peptide it degrades with heat and repeated freeze-thaw, so solution is typically refrigerated [2]. These are general research-supply handling notes, not a clinical preparation or dosing instruction, and research-grade purity is unverified [3]. ## How long does ipamorelin stay in your system? In healthy human volunteers, ipamorelin's terminal half-life is approximately two hours, with the growth-hormone pulse it triggers peaking near 40 minutes after a dose [2]. Systemic exposure is therefore short-lived. In rats, plasma clearance is roughly five-fold lower than GHRP-6, with 60 to 80 percent of a dose recovered intact in bile and urine [5]. ## Does ipamorelin make you hungry? It can, by mechanism. Ipamorelin acts on the ghrelin receptor, and ghrelin-receptor agonists activate the brain's appetite centers and induce feeding in animals [12]. Users often report increased appetite after a dose, described as milder than with GHRP-6 but still noticeable [12]. This is a class-level orexigenic signal built into how the peptide works. ## Will I gain weight on ipamorelin? There is no human weight-outcome data. In mice, ipamorelin raised fat-pad weight and leptin, partly independent of growth hormone [10], and its appetite-raising mechanism could increase intake [12]. Its one human trial was a short perioperative course not designed to measure weight [3]. Any weight change is unverified and confounded by diet and activity. ## Does ipamorelin increase appetite? Yes, by mechanism it can. As a ghrelin-receptor agonist, ipamorelin engages the same pathway the hunger hormone uses; central administration of ghrelin and GH secretagogues induces feeding in rats [12]. Community reports describe an appetite uptick after injection, generally milder than with GHRP-6 [12]. It is a recognized class-level effect, not a clinical finding in humans. ## What does ipamorelin peptide do? It releases a pulse of growth hormone by selectively activating the ghrelin receptor on pituitary cells, without raising cortisol or prolactin [1]. In animals this drives faster bone growth [4] and added bone mineral content [8]. In humans, its evidence is limited and its one efficacy trial missed [3], so its human effects are not established by controlled data. ## How long does it take for ipamorelin to work? Pharmacologically, fast: the growth-hormone pulse peaks near 40 minutes after a dose in humans [2]. For the effects people care about, the picture is anecdotal — community reports describe sleep changes within one to two weeks, with body-composition shifts noted only over weeks to months, all unverified [3]. No controlled human onset data exist for those outcomes. ## Does ipamorelin cause water retention? Mild water retention is occasionally reported by users (anecdotal), described as milder than with older GHRP compounds and often settling with continued use [3]. Mechanistically it is plausible: growth-hormone excess is associated with sodium and water retention [6]. No controlled human study has measured fluid balance on ipamorelin at research-use doses [3]. --- An md-desk reading of the ipamorelin record, led by the rat bone-growth data and kept honest about where the human evidence thins — every figure carried back to its study, no clinic behind the name and nothing dispensed.